Page last updated: 2024-12-06

ropinirole hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Ropinirole hydrochloride is a dopamine agonist that is used to treat Parkinson's disease and restless legs syndrome. It is synthesized in a multi-step process that involves several chemical reactions. Ropinirole hydrochloride works by stimulating dopamine receptors in the brain. This can help to improve motor function in people with Parkinson's disease and reduce the symptoms of restless legs syndrome. Ropinirole hydrochloride is an important drug because it can help people with these conditions to live more normal lives. It is studied to learn more about its effects on the brain and body, as well as to develop new and improved treatments for Parkinson's disease and restless legs syndrome.'

Cross-References

ID SourceID
PubMed CID68727
CHEMBL ID1200411
CHEBI ID8889
SCHEMBL ID40760
MeSH IDM0322477

Synonyms (109)

Synonym
AC-735
AKOS015844988
nvd-434
sk&f-101468a
np-201
adartrel
hp-3000
requip
jzp-7
ropinirole hydrochloride
requip xl
repreve
requip xr
requip lp
requip pr
requip cr
sk&f 101468-a
2(h)-indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-, monohydrochloride
1,3-dihydro-4-(2-(dipropylamino)ethyl)-2h-indol-2-one monohydrochloride
4-(2-(dipropylamino)ethyl)-2-indolinone monohydrochloride
ropinirole hydrochloride [usan]
c16h24n2o.hcl
EU-0101101
D00784
requip (tn)
91374-20-8
ropinirole hydrochloride (jan/usp)
NCGC00094373-01
R 4152
skf 101468; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2h-indol-2-one hydrochloride
ropinirole hcl
CHEMBL1200411
ropinirole (as hydrochloride)
sk&f-101468-a
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one hydrochloride
A843815
4-(2-(dipropylamino)ethyl)indolin-2-one hydrochloride
S3189
c16h25cln2o
ropinirole hydrochloride [usan:usp]
unii-d7zd41rzi9
d7zd41rzi9 ,
FT-0642200
MLS003899234
smr001456484
skf-101468a
4-[2-(dipropylamino)ethyl]-1,3-dihydro-2h-indol-2-one hydrochloride
skf 101468 hydrochloride
LP01101
ropinirole hydrochloride [who-dd]
ropinirole hydrochloride [jan]
4-[2-(dipropylamino)ethyl]-2-indolinone monohydrochloride
ropinirole hydrochloride [mart.]
ropinirole hydrochloride [usp monograph]
ropinirole hydrochloride [usp-rs]
2h-indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-, monohydrochloride
ropinirole hydrochloride [ep monograph]
ropinirole hydrochloride [vandf]
ropinirole hydrochloride [orange book]
4-(2-(dipropylamino)ethyl)-1,3-dihydro-2h-indol-2-one monohydrochloride
ropinirole hydrochloride [mi]
CCG-213346
HY-B0623A
ropinirole (hydrochloride)
SCHEMBL40760
BS-1020
XDXHAEQXIBQUEZ-UHFFFAOYSA-N
4-(2-di-n-propylaminoethyl)-2(3h)indolone hydrochloride
4-(2-di-n-propylaminoethyl)-2(3h)-indolone hydrochloride
NCGC00261786-01
tox21_501101
4-(2-dipropylamino-ethyl)-1,3-dihydro-indol-2-one
ropinirolhydrochloride
ropinirolehydrochloride
mfcd01754173
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one;hydrochloride
DTXSID50238533 ,
AC-736
SR-01000076215-2
sr-01000076215
ropinirole hydrochloride, united states pharmacopeia (usp) reference standard
ropinirole hydrochloride, powder, >=98% (hplc)
ropinirole hydrochloride, europepharmacopoeia (ep) reference standard
ropinirole hydrochloride, pharmaceutical secondary standard; certified reference material
ropinirole for peak identification 1, europepharmacopoeia (ep) reference standard
ropinirole for peak identification 2, europepharmacopoeia (ep) reference standard
CHEBI:8889
SR-01000076215-5
SW199044-2
4-[2-(dipropylamino)ethyl]-1,3-dihy dro-2h-indol-2-one hydrochloride
HB1923
Z1521553578
requi
BCP02130
EX-A4943
4-[2-(dipropylamino)ethyl]-2,3-dihydro-1h-indol-2-one hydrochloride
EN300-119502
Q27276228
ropinirole for peak identification 1
ropinirole for peak identification 3
ropinirole for peak identification 2
requipxl
ropinirole hydrochloride (mart.)
91374-21-9 , ropinirole
ropinirole hydrochloride (usan:usp)
ropinirole hydrochloride (ep monograph)
dtxcid00161024
ropinirole hydrochloride (usp-rs)
ropinirole hydrochloride (usp monograph)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolesAny compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency44.66840.003245.467312,589.2998AID1705
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency56.23410.540617.639296.1227AID2364; AID2528
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency10.00000.01789.637444.6684AID588834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID690721Reversal of reserpine-induced akinesia in Sprague-Dawley rat at 5 umol/kg, sc administered 18 hrs post reserpine challenge measured for 6 hrs2012Journal of medicinal chemistry, 06-28, Volume: 55, Issue:12
Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agoni
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1265369Reversal of reserpine-induced hypolocomotion in Sprague-Dawley rat at 10 umol/kg, ip administered 18 hrs post reserpine challenge measured for 6 hrs relative to reserpine-treated control2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 59.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index59.39 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index91.96 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (59.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]